1. Home
  2. FTF vs DVAX Comparison

FTF vs DVAX Comparison

Compare FTF & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTF
  • DVAX
  • Stock Information
  • Founded
  • FTF 2003
  • DVAX 1996
  • Country
  • FTF United States
  • DVAX United States
  • Employees
  • FTF N/A
  • DVAX N/A
  • Industry
  • FTF Finance/Investors Services
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FTF Finance
  • DVAX Health Care
  • Exchange
  • FTF Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • FTF 1.9B
  • DVAX 1.7B
  • IPO Year
  • FTF N/A
  • DVAX 2004
  • Fundamental
  • Price
  • FTF $6.57
  • DVAX $12.48
  • Analyst Decision
  • FTF
  • DVAX Buy
  • Analyst Count
  • FTF 0
  • DVAX 2
  • Target Price
  • FTF N/A
  • DVAX $23.00
  • AVG Volume (30 Days)
  • FTF 153.9K
  • DVAX 1.8M
  • Earning Date
  • FTF 01-01-0001
  • DVAX 02-20-2025
  • Dividend Yield
  • FTF 11.45%
  • DVAX N/A
  • EPS Growth
  • FTF N/A
  • DVAX N/A
  • EPS
  • FTF N/A
  • DVAX 0.15
  • Revenue
  • FTF N/A
  • DVAX $260,810,000.00
  • Revenue This Year
  • FTF N/A
  • DVAX $21.64
  • Revenue Next Year
  • FTF N/A
  • DVAX $19.81
  • P/E Ratio
  • FTF N/A
  • DVAX $82.58
  • Revenue Growth
  • FTF N/A
  • DVAX N/A
  • 52 Week Low
  • FTF $5.76
  • DVAX $9.74
  • 52 Week High
  • FTF $6.56
  • DVAX $14.41
  • Technical
  • Relative Strength Index (RSI)
  • FTF 49.91
  • DVAX 41.74
  • Support Level
  • FTF $6.53
  • DVAX $12.02
  • Resistance Level
  • FTF $6.66
  • DVAX $13.17
  • Average True Range (ATR)
  • FTF 0.08
  • DVAX 0.34
  • MACD
  • FTF 0.01
  • DVAX -0.07
  • Stochastic Oscillator
  • FTF 59.26
  • DVAX 40.00

About FTF Franklin Limited Duration Income Trust of Beneficial Interest

Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: